This is why I've sat on the sidelines.
For many companies, stem cells have been a case of "I've got this neat thing, let's see if it works on something", which is sometimes a viable strategy but requires a lot of studies and May amount to nothing.
A concern I have going forward is how they've mentioned the Novartis partnership at the bottom of the announcement today, specifically the Hart-Scott-Rodino antitrust improvements act.
I don't know much about the act but I did some googling.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-496
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.030(2.61%) |
Mkt cap ! $1.347B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.19 | $1.14 | $9.588M | 8.196M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 113915 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 81953 | 8 |
View Market Depth
| Last trade - 16.10pm 23/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.18 |
Change
0.030 ( 2.82 %) |
||||
| Open | High | Low | Volume | ||
| $1.14 | $1.20 | $1.14 | 1665531 | ||
| Last updated 15.59pm 23/05/2024 ? | |||||
| MSB (ASX) Chart |